European Union - English - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol acetate, mometasone furoate - asthma - drugs for obstructive airway diseases, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - asthma - drugs for obstructive airway diseases, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

European Union - English - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol, mometasone furoate - asthma - drugs for obstructive airway diseases, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - indacaterol maleate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - hirobriz breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.

European Union - English - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol maleate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - oslif breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.

European Union - English - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol maleate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - onbrez breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide - pulmonary disease, chronic obstructive - adrenergics in combinations with anticholinergics incl. triple combinations with corticosteroids - xoterna breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide - pulmonary disease, chronic obstructive - adrenergics in combinations with anticholinergics incl. triple combinations with corticosteroids, drugs for obstructive airway diseases, - ultibro breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - indacaterol maleate 0.194mg;  ;  ;   - powder filled inhalation capsule - 150 mcg - active: indacaterol maleate 0.194mg       excipient: gelatin lactose monohydrate opacode black s-1-277002 - onbrez® breezhaler® is a long-acting beta2-agonist indicated for long-term, once-daily, maintenance bronchodilator treatment of airflow limitation in patients with chronic obstructive pulmonary disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - indacaterol maleate 0.389mg;  ;  ;   - powder filled inhalation capsule - 300 mcg - active: indacaterol maleate 0.389mg       excipient: gelatin lactose monohydrate opacode - onbrez® breezhaler® is a long-acting beta2-agonist indicated for long-term, once-daily, maintenance bronchodilator treatment of airflow limitation in patients with chronic obstructive pulmonary disease.